NICE-aligned management typically involves: Addressing modifiable risk factors (smoking cessation, weight loss, increased physical activity, alcohol reduction) Optimising management of underlying conditions (diabetes, hypertension, depression) Trial of PDE5 inhibitor therapy Referral to specialist services (urology/andrology) if first-line treatments fail or where structural/neurological/endocrine causes are suspected Consideration of psychosexual therapy where appropriate Men should be reassured that ED is a medical condition with effective treatments, and seeking help through proper channels ensures safety, appropriate investigation of underlying causes, and access to evidence-based therapies
they are not a topical formulation percentage and cannot be read across to one
It was a year defined by effect sizes, first-line shifts, and disease-modifying signals that are already changing real clinical decision-making
Severe or worsening pain and exhaustion
Are we looking for other targets as well
Unlike Melanotan I/II or full-length alpha-MSH, KPV does not bind melanocortin receptors (MC1R, MC3R, MC5R)
